Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
Key Highlights
- ➤Top-line Entolimod efficacy results anticipated in early December
- ➤NIAID is funding Entolimod’s therapeutic GI-ARS study
- ➤Entolimod is being evaluated as a single-dose post-radiation treatment
- ➤Valion Bio (VBIO) will discuss Entolimod at Baird’s November 17 conference
Expert Statements
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We hope U.S. service members never face a nuclear or radiological incident. But if they do, the military needs medical options it can use in the field.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“With imminent NIAID-funded efficacy data on the horizon and clear legislative momentum from the House Armed Services Committee, our participation at RW Baird's National Security Conference provides a timely platform to engage directly with defense stakeholders on the potential of Entolimod to meet their immediate preparedness requirements.”
SAN ANTONIO, TX / ACCESS Newswire / November 11, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today, on Veterans Day, announced that it will attend RW Baird's 2026 National Security Conference on November 17 in Washington, D.C. In conversations with defense stakeholders and institutional investors at the conference, management will discuss how Entolimod, Valion's lead biologic drug candidate, could help protect U.S. service members from the effects of radiation exposure.
Following positive findings in a preclinical safety study, Valion is currently working with the government to evaluate whether a single dose of Entolimod given 24 hours after radiation exposure improves survival in an animal model of gastrointestinal acute radiation syndrome (GI-ARS). The National Institute of Allergy and Infectious Diseases ("NIAID") is funding the therapeutic study through its Radiation and Nuclear Countermeasures Program. Top-line results are anticipated in early December.
Get started
Create a free account to read the full story.